Melanotan II came out of a research program at the University of Arizona that started with a straightforward question: could you pharmacologically trigger melanin production to protect skin from UV damage? The goal was a compound that would increase pigmentation without requiring UV exposure, potentially reducing skin cancer risk.
The research produced a cyclic peptide with potent melanocortin receptor activity, and the 1996 pilot clinical study showed it did exactly what the preclinical research predicted. The melanocortin receptor biology turned out to be more interesting than just tanning, though, and that complexity is what makes MT-2 a substantive research subject.
Key Takeaways
- MT-2 (Melanotan II) is a cyclic synthetic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH)
- Developed at the University of Arizona as a successor to afamelanotide (Melanotan I)
- Activates melanocortin receptors, particularly MC1R (pigmentation) and MC4R (appetite, other effects)
- Non-selective melanocortin receptor agonist with documented activity across the receptor family
- 1996 Phase I clinical study demonstrated tanning activity in humans with only 5 doses
- The melanocortin system has roles beyond pigmentation, making MT-2 research relevant to multiple biological areas
What Is MT-2?
Melanotan II is a cyclic heptapeptide (seven amino acids) and a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). The “II” designation distinguishes it from afamelanotide (Melanotan I), a linear analog that preceded it in the Arizona research program.
Alpha-MSH is an endogenous peptide hormone derived from pro-opiomelanocortin (POMC), a precursor protein that also produces ACTH, beta-endorphin, and other signaling molecules. Alpha-MSH is the natural melanocortin receptor ligand most relevant to pigmentation, primarily activating MC1R on melanocytes to trigger melanin synthesis.
The cyclic structure of MT-2 was a design choice to improve potency and metabolic stability compared to the linear alpha-MSH sequence. Cyclization constrains the peptide’s conformation, which generally increases receptor binding affinity and reduces degradation by proteolytic enzymes. MT-2 is significantly more potent than alpha-MSH at melanocortin receptors as a result.
The non-selective receptor profile is an important research consideration. MT-2 activates not just MC1R (the pigmentation receptor) but also MC4R and other melanocortin receptors. This broader activity profile means the research effects span beyond pigmentation to other biological systems that melanocortin signaling regulates.
How Does MT-2 Work?
Melanocortin Receptor System
The melanocortin system comprises five receptors (MC1R-MC5R), each expressed in different tissues with different functions. Understanding which receptors MT-2 activates helps interpret the research effects.
MC1R is expressed on melanocytes, the pigment-producing cells in skin and hair follicles. Activation triggers increased melanin synthesis (specifically eumelanin, the dark brown/black pigment) and accelerated melanosome transfer to surrounding cells.
MC4R is expressed in the hypothalamus and plays a role in appetite regulation and energy balance. It’s also expressed in other CNS regions and peripheral tissues with additional functions.
MC3R is involved in energy homeostasis and body weight regulation. MC2R is the ACTH receptor (adrenal function). MC5R is found in exocrine glands.
MT-2 as a non-selective agonist engages multiple receptors simultaneously, which is why the research effects extend beyond pigmentation.
Melanogenesis Mechanism
At the cellular level, MC1R activation triggers a cAMP signaling cascade in melanocytes. Elevated cAMP activates protein kinase A, which activates MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte function. MITF drives expression of the enzymes responsible for melanin synthesis: tyrosinase, TRP-1, and TRP-2.
The result is increased melanin production and accelerated transfer of melanosomes (melanin-containing organelles) from melanocytes to surrounding keratinocytes, producing visible darkening of skin.
UV-Independent Pigmentation
The research significance of melanogenesis without UV exposure is the photoprotective hypothesis. Melanin absorbs UV radiation and limits DNA damage in skin cells. If pharmacological melanin induction could provide UV protection without requiring UV exposure for activation, it could reduce the UV dose needed to trigger protection.
What Does the Research Show?
1996 Phase I Clinical Study (PubMed PMID: 8637402)
The defining MT-2 clinical paper is the 1996 pilot Phase I study, which evaluated Melanotan II in human subjects. The study found that MT-2 demonstrated tanning activity in humans given only 5 low doses every other day by subcutaneous injection. Two subjects showed increased pigmentation that persisted after the study ended.
This was the proof-of-concept that the melanocortin receptor biology translated from preclinical models to human pigmentation. The low dose requirement and persistence of effect after stopping were notable findings.
The study also characterized the safety and tolerability profile at the doses tested, documenting the adverse event profile that subsequent research would build on.
Melanocortin Receptor Research Background
The broader melanocortin receptor literature, which MT-2 research draws from, has extensively characterized the biology of MC1R and its role in pigmentation variation across human populations. Natural variants in MC1R are associated with red hair and fair skin, establishing the receptor’s central role in pigmentation genetics.
This genetic biology provides context for the pharmacological research: MT-2 is activating a receptor system with well-established connections to pigmentation phenotype.
MC4R Research Connections
The MC4R activity of MT-2 connects it to a substantial literature on appetite regulation and energy balance. MC4R is a validated target in metabolic research, and understanding how MT-2’s MC4R activity compares to selective MC4R agonists is an active research question.
MT-2’s non-selective profile makes it a research tool for studying the melanocortin system broadly, while selective agonists allow isolation of individual receptor contributions.
Purity, Testing, and Quality Considerations
MT-2 is a cyclic peptide, and the cyclization must be correctly formed for the compound to have proper receptor binding characteristics. Linear (non-cyclic) MT-2 would have different biological activity than the cyclic form.
Mass spectrometry verification should confirm both the molecular weight and the cyclic structure (the mass difference between cyclic and linear forms is 2 Da, reflecting the loss of two hydrogen atoms in disulfide bridge or cyclization). HPLC purity at 98%+ is standard.
The correct disulfide bridge or amide bond forming the cycle should be verifiable in the analytical data. This is a specific quality requirement for cyclic peptides not applicable to linear peptide research compounds.
Research-grade MT-2 from Concordia Research Chems includes analytical documentation confirming the cyclic structure alongside standard purity analysis.
Related Compounds
MT-2’s melanocortin receptor specificity places it in a distinct research category. Within that category, the comparison most relevant to research design is with afamelanotide (Melanotan I), the linear alpha-MSH analog that preceded MT-2 in the Arizona research program.
Afamelanotide is MC1R-selective while MT-2 is non-selective, making the comparison between them useful for isolating MC1R-specific versus broader melanocortin effects. Afamelanotide has received EU regulatory approval for erythropoietic protoporphyria (EPP), establishing a clinical reference point.
Where the Research Is Heading
MT-2 research is proceeding along two main tracks. The pigmentation and photoprotection track continues examining whether the melanogenesis effects can be harnessed for UV protection research. The skin cancer prevention hypothesis from the original Arizona program is still an active research question.
The broader melanocortin receptor biology track is examining the connections between MC1R/MC4R activation and other physiological systems. The melanocortin system’s roles in energy balance, inflammation, and other functions connected to MT-2’s non-selective receptor profile are generating research interest beyond the original tanning focus.
The non-selective profile is both MT-2’s research strength (it’s a broad melanocortin system activator) and its practical limitation (separating receptor-specific effects requires careful experimental design with selective comparators).
Concordia Research Chems carries research-grade MT-2 for laboratory research. Melanocortin receptor biology is a well-established research field with well-characterized receptor pharmacology, and MT-2 provides a potent non-selective tool for studying the full scope of melanocortin system activity.
Not sure which compound fits your research goals?
Take our 60-second quiz →Get a personalized recommendation based on what you're studying.